A Phase 2 interventional study of Placebo and SHP655 in Acquired Thrombotic Thrombocytopenic Purpura (aTTP), sponsored by Shire. Completed at 24 sites in 7 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-12-01.
Sponsored by Shire (part of Takeda) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda — 3 open to participants now, 4 under way, 1 of them phase 3. Purpura, Thrombotic Thrombocytopenic · Takeda.
Among the 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda, this one is the only one that started in 2019, is one of 2 in phase 2, and was the 4th registered.
67 studies on the registry are indexed under Purpura, Thrombotic Thrombocytopenic; 18 are open to participants now.
Browse Purpura, Thrombotic Thrombocytopenic studies →3 of the 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda are open now, in 4 countries. Recruiting first, the newest first:
Takeda · Sites in Germany, Poland
Takeda · Sites in Austria, Germany
Takeda · Sites in Japan
By country, each count listing its studies:
Of the 16 Purpura, Thrombotic Thrombocytopenic studies recruiting now, 12 (75%) set no upper age limit and 1 (6%) stops at 75 or younger; 9 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2014; this study’s year is marked. 1 started in 2019.
This study's enrollment of 28 is close to the median of 30 across 34 interventional studies indexed under Purpura, Thrombotic Thrombocytopenic.
Median enrollment 29 across the 5 interventional studies, 46 across the 4 observational. Of the 5 that completed or were terminated, 2 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
1 of the studies in Purpura, Thrombotic Thrombocytopenic by Takeda that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04683003Phase 3TakedaA Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura | 2027-03-16 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Purpura, Thrombotic Thrombocytopenic by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the pharmacokinetics, safety, and efficacy of rADAMTS-13 (SHP655) administered in addition to standard of care (SoC) treatment of acquired thrombotic thrombocytopenic purpura (aTTP) participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participant has been diagnosed with primary or secondary acquired thrombotic thrombocytopenic purpura (aTTP) based on the following criteria:
a) Thrombocytopenia [drop in count >=50% or platelet count \<100,000/microlitre (μL)] i) No more than 3 participants per arm may be enrolled with a screening platelet count >= 50,000/μL.
b) Microangiopathic hemolytic anemia [elevation of lactate dehydrogenase (LDH) >2-fold or by presence or increase of schistocytes in peripheral blood smear].
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received SoC daily PEX followed by placebo immediately and 12 +/- 1 hours after completion of PEX until remission was achieved (up to approximately 6 months).
Other: Placebo · Other: Standard of Care
Participants received SoC daily PEX and SHP655 40 +/- 4 international units per kilogram (IU/kg), IV injection, QD, immediately after PEX and placebo 12 +/- 1 hours after completion of PEX until remission was achieved (up to approximately 6 months).
Other: Placebo · Drug: SHP655 · Other: Standard of Care
Participants received SoC daily PEX and SHP655 40 +/- 4 IU/kg, IV injection, BID, immediately after PEX and 12 +/- 1 hours after completion of PEX until remission was achieved (up to approximately 6 months).
Drug: SHP655 · Other: Standard of Care
Participants will receive injection of placebo matched to SHP655.
Participants will receive injection of SHP655.
Also known as: rADAMTS-13
Participants will receive PEX as Standard of Care (SOC).
Also known as: PEX
ADAMTS-13 Activity Levels
ADAMTS-13 Activity Levels was assessed by fluorescence resonance energy transfer (FRETS) ADAMTS13 activity, with or without SHP655 Supplementation. Schedule A (Days 1, 2, 3, 4, 6, 8, 11, and every 3 days thereafter) or Schedule B (Days 1, 2, 3, 5, 7, 9, 12, and every 3 days thereafter). Data is reported for multiple timepoints as Within 15 minutes pre-PEX and post-PEX; Within 15 minutes, 0.5-3 hours, 4-6 hours post end of investigational product (IP) infusion 1; Within 15 minutes, 0.5-3 hours post end IP infusion 2; 30 minutes pre-IP infusion 2 of Schedule A and Schedule B (up to Day 11 or 12).
Time frame: Up to Days 11 or 12
Platelet Count
The platelet counts are reported in units of 10\^9 per liter blood.
Time frame: Baseline and end of study (EOS) (up to approximately 15 months)
Lactate Dehydrogenase (LDH) Levels
The lactate dehydrogenase levels are reported.
Time frame: Baseline and EOS (up to approximately 15 months)
Dose(s) of SHP655 Needed to Achieve and Maintain Adequate Plasma Levels of rADAMTS-13
Dose(s) of SHP655 needed to achieve and maintain adequate plasma levels of rADAMTS-13 in order to support induction of remission and to reduce the number of PEX procedures needed for the treatment of acute aTTP episodes was assessed.
Time frame: From start of study drug administration up to 13 weeks (following remission up to 6 months)
PK/PD Temporal Relationship of Safety and Efficacy Parameter as a Function of ADAMTS-13 Activity
Parameters included platelet and LDH counts.
Time frame: Up to 6 months
Number of Participants With ADAMTS-13 Binding Antibodies Per Titer
Antibody titer indicates the level of the antibodies in a blood sample, defined as the greatest dilution (or lowest concentration) of the blood sample at which an antibody assay (such as ELISA for e.g.), still produces a detectable positive result. Data is presented per titer for ADA positive participants only.
Time frame: Baseline and EOS (up to approximately 15 months)
Inhibitory Autoantibodies (Nab) Titer Levels
NAb titers were summarized (median, minimum and maximum) at baseline and EOS per treatment arms, in those subjects with NAb positive results (NAb positive is defined as titer value \>=0.6 BU/mL).
Time frame: Baseline and EOS (up to approximately 15 months)
ADAMTS-13 Activity Levels in Participants Receiving Additional SHP655 for up to 30 Days After Resolution by Using FRETS
ADAMTS-13 activity levels in participants receiving additional SHP655 for up to 30 days after the resolution of the thrombotic thrombocytopenic purpura (TTP) episode were assessed. Resolution was defined as a normal platelet count and LDH \<2 ULN for at least 48 hours following initial normalization of platelet count (acute episode period).
Time frame: At Days 3, 7, 10, 21, 28, 42, 56 and 84
Relationship Between ADAMTS-13 Activity and End-organ Disease Status
End-organ disease status were evaluated for renal, cardiac and neurological diseases.
Time frame: Up to 6 months
Predose Concentration (Cpre) to Maximum Plasma Concentration (Cmax) Ratio
Time frame: Pre-PEX and post-PEX at multiple timepoints at Days 1, 2, 3, 4 or 5, 6 or 7, 8 or 9, and 11 or 12
AUC Overall: Area Under the Plasma Concentration Time Curve ADAMTS13 Activity by Using FRETS
Time frame: Within 15 min pre-PEX and at multiple timepoints Post PEX at Days 1, 2, 3, 4 or 5 and 6 or 7
Systemic and Antibody Induced Clearance
Time frame: 15 minutes pre-PEX,15 minutes post-PEX,15 minutes, 0.5-3 hours, 4-6 hours post end of IP infusion 1,30 minutes pre-IP infusion 2,15 minutes, 0.5-3 hours post-IP infusion 2 of Schedule A or Schedule B (up to 6 months)
Cmax: Maximum ADAMTS-13 Activity Between PEX or SHP655 Infusions by Using FRETS
Time frame: Pre-PEX and post-PEX at multiple timepoints at Days 1, 2, 3, 4 or 5, 6 or 7, 8 or 9, and 11 or 12
Trough Levels of ADAMTS-13 Prior PEX ADAMTS13 Activity by Using FRETS
Time frame: Within 15 min pre-PEX and at multiple timepoints Post PEX at Days 2, 3, 4 or 5 and 6 or 7
Percentage of Participants With ADAMTS-13 Activity Trough Levels >10%
Time frame: Pre-dose at Days 2, 3 4 or 5, 6 or 7, 8 or 9, and 11 or 12
Number of Participants Who Achieved Remission Following Normalization of Platelet Count
Remission was defined as the time taken to achieve platelet count ≥150,000/μL, which was confirmed by a second normal platelet count ≥150,000/μL and LDH \<2 ULN 48 hours following initial normalization.
Time frame: From the start of study drug administration up to 6 months post remission
Percentage of Participants Achieving Remission
Remission was defined as a normal platelet count and LDH \<2 upper limit of normal (ULN) for at least 48 hours following initial normalization of platelet count (acute episode period). Normalization of platelet count was defined ≥150,000/μL, which was confirmed by a second normal platelet count ≥150,000/μL and LDH \<2 ULN.
Time frame: From the start of study drug administration up to 6 months post remission
Time to First Exacerbation
Exacerbation was defined as recurrent thrombocytopenia following a response and requiring a reinitiation of daily plasma exchange treatment after ≥1 day but ≤30 days of no plasma exchange treatment. Data is reported based on Kaplan-Meier estimates. Data was reported for time to first exacerbation in categories for participants enrolled before protocol amendment 4 (from study start up to 11 months) and after protocol amendment 4 (from 11 months up to the EOS).
Time frame: From start of study drug administration up to EOS (up to approximately 15 months)
Time to Relapse
Relapse was determined by platelet count or the occurrence after remission of a major clinical event (e.g., Myocardial Infraction (MI), stroke, death) deemed by the investigator to be related to aTTP. Data was reported for time to relapse in categories for participants enrolled before protocol amendment 4 (from study start up to 11 months) and after protocol amendment 4 (from 11 months up to the EOS).
Time frame: From start of study drug administration up to EOS (up to approximately 15 months)
Percentage of Participants With Exacerbation
Exacerbation was determined by platelet count or the occurrence after remission of a major clinical event (e.g., myocardial infarction (MI), stroke, death) deemed by the investigator to be related to aTTP. Data was reported for percentage of participants with exacerbation in categories for participants enrolled before protocol amendment 4 (from study start up to 11 months) and after protocol amendment 4 (from 11 months up to the EOS).
Time frame: From start of study drug administration up to EOS (up to approximately 15 months)
Percentage of Participants With Relapse
Relapse was determined by platelet count or the occurrence after remission of a major clinical event (e.g., Myocardial Infraction (MI), stroke, death) deemed by the investigator to be related to aTTP. Data was reported for percentage of participants with exacerbation in categories for participants enrolled before protocol amendment 4 (from study start up to 11 months) and after protocol amendment 4 (from 11 months up to the EOS).
Time frame: From start of study drug administration up to EOS (up to approximately 15 months)
Percentage of Participants With Major Clinical Events Related to Thrombotic Thrombocytopenic Purpura (TTP)
Major clinical events related to TTP included Death, Stroke, MI and organ dysfunction not normalized within the 90-day observation period which consisted of chronic renal insufficiency, neurologic impairment and neurocognitive deficits.
Time frame: From start of study drug administration up to EOS (up to approximately 15 months)
Number of Participants With Major Clinical Events Related to PEX
Major clinical events included clinically relevant bleeding (modified ITP score) or thrombosis at the site of line insertion, adverse reactions to plasma, including citrate reactions, allergic reactions, and transfusion-related acute lung injury (TRALI). Data is reported by summarizing the data for all parameters.
Time frame: Up to 6 months
Number of Participants With Anti-drug Antibody (ADA) Titer of Binding Relative to Baseline
Time frame: Baseline and EOS (at approximately Month 15)
Number of Participants With Inhibitory Antibodies Relative to Baseline
Time frame: Baseline and EOS (at approximately Month 15)
Percentage of Participants With at Least One Positive Identification of Antibodies to SHP655
Percentages are based on the total number of participants per treatment group that have at least one ADA sample analyzed.
Time frame: Up to 6 months
Number of Participants With Treatment Emergent Adverse Events (TEAEs), Specifically Product-Related TEAEs and Serious TEAEs
AE=any untoward medical occurrence in a participants administered IP that does not necessarily have a causal relationship with the treatment. TEAE=an adverse event with an onset that occurs after receiving study drug. SAE=an AE with any untoward clinical manifestation of signs, symptoms or outcomes which results in death, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, results in a congenital abnormality/birth defect, important medical event, bronchospasm associated with anaphylaxis, reviewed and confirmed seroconversion for human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis E virus (HEV), or parvovirus B19 (B19V). A product related AE is any event emerging or manifesting at or after the initiation of treatment with an investigational product or medicinal product or any existing event that worsens.
Time frame: From first dose of study drug until the EOS (up to approximately 15 months)
Number of Participants With Clinically Relevant Changes in Vital Signs
Vital signs were assessed based on blood pressure, pulse rate, respiratory rate and body temperature.
Time frame: From first dose of study drug until the EOS (up to approximately 15 months)
Number of Participants With Clinically Relevant Changes in Clinical Chemistry
Clinical chemistry assessed alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, alkaline phosphatase, blood urea nitrogen, creatinine, and glucose.
Time frame: From first dose of study drug until the EOS (up to approximately 15 months)
Number of Participants With Clinically Relevant Changes in Hematology
Hematology consisted of complete blood count and leukocytes with differential (basophils, eosinophils, lymphocytes, monocytes, neutrophils), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC) and platelet count.
Time frame: From first dose of study drug until the EOS (up to approximately 15 months)
Percentage of Participants Receiving Rescue Therapy
Rescue therapy was defined as any product with a known interruption to the pharmacokinetic/ pharmacodynamic (PK/PD) relationship between ADAMTS-13 activity, von Willebrand factor (VWF) activity, and platelet count. If rescue therapy was initiated, the administration of IP (SHP655 or placebo) was suspended for the duration of the study. Number of participants experiencing occurrence of receiving rescue therapy was assessed.
Time frame: From first dose of study drug until the EOS (up to approximately 15 months)
Percentage of Participants Meeting Rescue Criteria
Rescue therapy was defined as any product with a known interruption to the PK/PD relationship between ADAMTS-13 activity, VWF activity, and platelet count. If rescue therapy was initiated, the administration of IP (SHP655 or placebo) was suspended for the duration of the study. Number of participants experiencing occurrence in meeting rescue therapy criteria was assessed. Percentage of participants with rescue therapy initiated are based on laboratory criteria and adverse events.
Time frame: From first dose of study drug until the EOS (up to approximately 15 months)
Participants took part in the study at 12 investigative sites in Canada, France, Great Britain, Spain and United States from 09 October 2019 to 05 August 2021.
| Milestone | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Started | 10 | 9 | 9 |
| Pharmacokinetic population | 10 | 8 | 9 |
| Completed | 9 | 6 | 8 |
| Not completed | 1 | 3 | 1 |
| Withdrew: Not meeting confirmatory inclusion criteria | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Reason not specified | 0 | 2 | 1 |
ADAMTS-13 Activity Levels was assessed by fluorescence resonance energy transfer (FRETS) ADAMTS13 activity, with or without SHP655 Supplementation. Schedule A (Days 1, 2, 3, 4, 6, 8, 11, and every 3 days thereafter) or Schedule B (Days 1, 2, 3, 5, 7, 9, 12, and every 3 days thereafter). Data is reported for multiple timepoints as Within 15 minutes pre-PEX and post-PEX; Within 15 minutes, 0.5-3 hours, 4-6 hours post end of investigational product (IP) infusion 1; Within 15 minutes, 0.5-3 hours post end IP infusion 2; 30 minutes pre-IP infusion 2 of Schedule A and Schedule B (up to Day 11 or 12).
| international units(IU)/ml | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| FRETS: Day 1: ≤15 min Pre-PEX | 0.1439 ± 0.19247 | NA ± NA | NA ± NA |
| FRETS: Day 1: ≤15 min Post-PEX | 0.5418 ± 0.18345 | 0.5011 ± 0.19236 | 0.3029 ± 0.29020 |
| FRETS: Day 1: ≤15 min Post End of IP 1 | 0.4571 ± 0.19125 | 2.012 ± 0.82832 | 1.352 ± 0.93502 |
| FRETS: Day 1: 0.5-3 Hour (hr) Post End of IP 1 | 0.4420 ± 0.20895 | 1.905 ± 0.83349 | 1.266 ± 0.98904 |
| FRETS: Day 1: 4-6 hr Post End of IP 1 | 0.3197 ± 0.20545 | 1.163 ± 0.61343 | 0.7912 ± 0.69403 |
| FRETS: Day 1: ≤30 min Pre-IP 2 | 0.2108 ± 0.19731 | 1.027 ± 0.55951 | 0.4949 ± 0.54891 |
| FRETS: Day 1: ≤15 min Post End of IP 2 | 0.2267 ± 0.18660 | 1.022 ± 0.52060 | 1.545 ± 1.0854 |
| FRETS: Day 1: 0.5-3 hr Post End of IP 2 | 0.2007 ± 0.20012 | 1.015 ± 0.56462 | 1.300 ± 1.1114 |
| FRETS: Day 2: ≤15 min Pre-PEX | 0.1691 ± 0.15909 | 0.7650 ± 0.61929 | 0.9482 ± 0.99771 |
| FRETS: Day 2: ≤15 min Post-PEX | 0.5801 ± 0.16107 | 0.7808 ± 0.36544 | 0.8426 ± 0.54317 |
| FRETS: Day 2: ≤15 min Post End of IP 1 | 0.5433 ± 0.20267 | 1.965 ± 0.72122 | 1.977 ± 0.98427 |
| FRETS: Day 2: 0.5-3 hr Post End of IP 1 | 0.5281 ± 0.24842 | 2.105 ± 1.0656 | 2.153 ± 1.3856 |
| FRETS: Day 2: 4-6 hr Post End of IP 1 | 0.4170 ± 0.25202 | 1.622 ± 0.78046 | 1.411 ± 0.75100 |
| FRETS: Day 2: ≤30 min Pre-IP 2 | 0.3117 ± 0.24934 | 1.309 ± 0.48787 | 1.044 ± 0.55923 |
| FRETS: Day 2: ≤15 min Post End of IP 2 | 0.2998 ± 0.24960 | 1.283 ± 0.52550 | 1.960 ± 0.99952 |
| FRETS: Day 2: 0.5-3 hr Post End of IP 2 | 0.2833 ± 0.23999 | 1.398 ± 0.47591 | 2.129 ± 1.4547 |
| FRETS: Day 3: ≤15 min Pre-PEX | 0.2468 ± 0.23669 | 1.044 ± 0.54178 | 1.129 ± 1.0570 |
| FRETS: Day 3: ≤15 min Post-PEX | 0.5342 ± 0.22251 | 0.7786 ± 0.16455 | 0.7020 ± 0.40432 |
| FRETS: Day 3: ≤15 min Post End of IP 1 | 0.5215 ± 0.23522 | 2.210 ± 0.96057 | 1.911 ± 1.6633 |
| FRETS: Day 3: 0.5-3 hr Post End of IP 1 | 0.4970 ± 0.23979 | 2.086 ± 0.85567 | 1.785 ± 1.1566 |
| FRETS: Day 3: 4-6 hr Post End of IP 1 | 0.4670 ± 0.30646 | 1.680 ± 0.46457 | 1.271 ± 0.71567 |
| FRETS: Day 3: ≤30 min Pre-IP 2 | 0.3424 ± 0.29275 | 1.196 ± 0.44550 | 1.041 ± 0.84152 |
| FRETS: Day 3: ≤15 min Post End of IP 2 | 0.3514 ± 0.31264 | 1.263 ± 0.38468 | 1.478 ± 1.0343 |
| FRETS: Day 3: 0.5-3 hr Post End of IP 2 | 0.3227 ± 0.28191 | 1.267 ± 0.43580 | 1.902 ± 1.4522 |
| FRETS: Day 4 or 5: ≤15 min Pre-PEX | 0.2378 ± 0.30513 | 1.094 ± 0.67793 | 1.378 ± 1.1964 |
| FRETS: Day 4 or 5: ≤15 min Post-PEX | 0.4554 ± 0.26405 | 0.8222 ± 0.21072 | 0.8725 ± 0.57834 |
| FRETS: Day 4 or 5: ≤15 min Post End of IP 1 | 0.7599 ± 1.0062 | 2.257 ± 0.95791 | 1.679 ± 1.3803 |
| FRETS: Day 4 or 5: 0.5-3 hr Post End of IP 1 | 0.6699 ± 0.76875 | 2.425 ± 1.4869 | 1.405 ± 1.0118 |
| FRETS: Day 4 or 5: 4-6 hr Post End of IP 1 | 0.5663 ± 0.69581 | 1.741 ± 0.84171 | 1.214 ± 1.0280 |
| FRETS: Day 4 or 5: ≤30 min Pre-IP 2 | 0.5045 ± 0.60730 | 1.290 ± 0.64745 | 1.255 ± 0.98796 |
| FRETS: Day 4 or 5: ≤15 min Post End of IP 2 | 0.4596 ± 0.58498 | 1.288 ± 0.63801 | 2.306 ± 1.6006 |
| FRETS: Day 4 or 5: 0.5-3 hr Post End of IP 2 | 0.4129 ± 0.49574 | 1.106 ± 0.59034 | 2.009 ± 1.4354 |
| FRETS: Day 6 or 7: ≤15 min Pre-PEX | 0.1246 ± 0.24910 | NA ± NA | NA ± NA |
| FRETS: Day 6 or 7: ≤15 min Post-PEX | 0.2587 ± 0.30131 | 0.7311 ± 0.48855 | NA ± NA |
| FRETS: Day 6 or 7: ≤15 min Post End of IP 1 | 0.2150 ± 0.26924 | 1.481 ± 0.89773 | NA ± NA |
| FRETS: Day 6 or 7: 0.5-3 hr Post End of IP 1 | 0.2194 ± 0.24929 | 1.673 ± 1.0721 | NA ± NA |
| FRETS: Day 6 or 7: 4-6 hr Post End of IP 1 | 0.1443 ± 0.24485 | 1.467 ± 1.1232 | NA ± NA |
| FRETS: Day 6 or 7: ≤30 min Pre-IP 2 | 0.1272 ± 0.25440 | NA ± NA | NA ± NA |
| FRETS: Day 6 or 7: ≤15 Minutes Post End of IP 2 | 0.1422 ± 0.28435 | NA ± NA | NA ± NA |
| FRETS: Day 6 or 7: 0.5-3 hr Post End of IP 2 | 0.1336 ± 0.26710 | NA ± NA | NA ± NA |
| FRETS: Day 8 or 9: ≤15 min Pre-PEX | — | NA ± NA | — |
| FRETS: Day 8 or 9: ≤15 min Post-PEX | — | NA ± NA | — |
| FRETS: Day 8 or 9: ≤15 min Post End of IP 1 | — | NA ± NA | — |
| FRETS: Day 8 or 9: 0.5-3 hr Post End of IP 1 | — | NA ± NA | — |
| FRETS: Day 8 or 9: 4-6 hr Post End of IP 1 | — | NA ± NA | — |
| FRETS: Day 8 or 9: ≤30 Minutes Pre-IP 2 | — | NA ± NA | — |
| FRETS: Day 8 or 9: ≤15 min Post End of IP 2 | — | NA ± NA | — |
| FRETS: Day 8 or 9: 0.5-3 hr Post End of IP 2 | — | NA ± NA | — |
| FRETS: Day 11 or 12: ≤15 min Pre-PEX | — | NA ± NA | — |
| FRETS: Day 11 or 12: ≤15 min Post-PEX | — | NA ± NA | — |
| FRETS: Day 11 or 12: ≤30 min Pre-IP 2 | — | NA ± NA | — |
| FRETS: Day 11 or 12: ≤15 min Post End of IP 2 | — | NA ± NA | — |
| FRETS: Day 11 or 12: 0.5-3 hr Post End of IP 2 | — | NA ± NA | — |
The platelet counts are reported in units of 10\^9 per liter blood.
| 10^9 platelets/L | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Baseline | 35.80 ± 32.076 | 27.67 ± 17.571 | 15.38 ± 7.463 |
| EOS | 278.89 ± 79.592 | 267.00 ± 86.906 | 286.22 ± 109.264 |
The lactate dehydrogenase levels are reported.
| international units (IU)/L | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Baseline | 634.6 ± 378.37 | 616.3 ± 478.14 | 787.8 ± 188.39 |
| EOS | 197.3 ± 42.00 | 208.8 ± 75.20 | 220.4 ± 69.93 |
Dose(s) of SHP655 needed to achieve and maintain adequate plasma levels of rADAMTS-13 in order to support induction of remission and to reduce the number of PEX procedures needed for the treatment of acute aTTP episodes was assessed.
No measurements were reported for this outcome.
Parameters included platelet and LDH counts.
No measurements were reported for this outcome.
Antibody titer indicates the level of the antibodies in a blood sample, defined as the greatest dilution (or lowest concentration) of the blood sample at which an antibody assay (such as ELISA for e.g.), still produces a detectable positive result. Data is presented per titer for ADA positive participants only.
| Participants | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Baseline- 1:20 | 2 | 3 | 1 |
| Baseline- 1:40 | 3 | 2 | 2 |
| Baseline- 1:80 | 2 | 0 | 1 |
| Baseline- 1:160 | 0 | 1 | 2 |
| Baseline- 1:320 | 0 | 2 | 0 |
| Baseline- 1:640 | 0 | 0 | 1 |
| Baseline- 1:1280 | 0 | 0 | 1 |
| EOS- 1:20 | 0 | 1 | 0 |
| EOS- 1:40 | 2 | 0 | 1 |
| EOS- 1:80 | 1 | 0 | 2 |
| EOS- 1:2560 | 0 | 1 | 0 |
| EOS- 1:5120 | 0 | 0 | 1 |
| EOS- 1:81920 | 0 | 0 | 1 |
NAb titers were summarized (median, minimum and maximum) at baseline and EOS per treatment arms, in those subjects with NAb positive results (NAb positive is defined as titer value \>=0.6 BU/mL).
| BU/mL | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Baseline | 1.25 (0.6 to 3.4) | 1.25 (1.0 to 1.8) | 1.80 (0.6 to 4.0) |
| EOS | 0.60 (0.6 to 0.6) | 0.70 (0.7 to 1.7) | 4.00 (4.0 to 4.0) |
ADAMTS-13 activity levels in participants receiving additional SHP655 for up to 30 days after the resolution of the thrombotic thrombocytopenic purpura (TTP) episode were assessed. Resolution was defined as a normal platelet count and LDH \<2 ULN for at least 48 hours following initial normalization of platelet count (acute episode period).
| IU/mL | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Day 3 | 0.4602 ± 0.14328 | NA ± NA | 0.1171 ± 0.28688 |
| Day 7 | 0.3037 ± 0.26921 | 0.3180 ± 0.34714 | NA ± NA |
| Day 10 | 0.9021 ± 0.20520 | 0.5518 ± 0.33962 | 0.4904 ± 0.46441 |
| Day 21 | 0.8102 ± 0.52773 | 0.6264 ± 0.60971 | 0.5320 ± 0.51432 |
| Day 28 | 0.8830 ± 0.51516 | 0.8931 ± 0.41323 | 0.8632 ± 0.62848 |
| Day 42 | 0.9968 ± 0.36745 | 0.8842 ± 0.39784 | 1.055 ± 0.36080 |
| Day 56 | 1.088 ± 0.25524 | 0.9923 ± 0.33663 | 1.092 ± 0.19961 |
| Day 84 | 0.9708 ± 0.43831 | 1.021 ± 0.65715 | 0.6051 ± 0.48113 |
End-organ disease status were evaluated for renal, cardiac and neurological diseases.
No measurements were reported for this outcome.
| ratio | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| FRETS: Day 1 | 2.744 ± 3.3837 | NA ± NA | NA ± NA |
| FRETS: Day 2 | 2.587 ± 0.92176 | 3.534 ± 2.4373 | 3.675 ± 2.3380 |
| FRETS: Day 3 | 1.669 ± 0.34045 | 2.134 ± 0.45392 | 2.268 ± 1.0679 |
| FRETS: Day 4 or 5 | NA ± NA | 2.543 ± 0.59576 | 1.972 ± 0.91248 |
| FRETS: Day 6 or 7 | NA ± NA | NA ± NA | NA ± NA |
| FRETS: Day 8 or 9 | — | NA ± NA | — |
| h*IU/mL | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Day 1 | 3.563 ± 2.5551 | 19.87 ± 9.1150 | 12.80 ± 8.4633 |
| Day 2 | 4.461 ± 3.9480 | 24.16 ± 9.0323 | 21.97 ± 11.135 |
| Day 3 | 5.590 ± 4.7232 | 22.75 ± 5.6549 | 23.49 ± 9.2589 |
| Day 4 or 5 | 9.507 ± 11.592 | 24.10 ± 11.357 | 22.05 ± 14.192 |
| Day 6 or 7 | NA ± NA | NA ± NA | NA ± NA |
No measurements were reported for this outcome.
| IU/mL | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Day 1 | 0.4157 ± 0.17075 | 2.011 ± 0.79036 | 1.653 ± 1.0655 |
| Day 2 | 0.4951 ± 0.27178 | 2.153 ± 1.1404 | 2.458 ± 1.4369 |
| Day 3 | 0.4307 ± 0.28420 | 2.228 ± 0.93968 | 2.222 ± 1.5080 |
| Day 4 or 5 | 0.6438 ± 0.97767 | 2.633 ± 1.4955 | 2.377 ± 1.5934 |
| Day 6 or 7 | 0.1362 ± 0.095283 | 1.625 ± 1.0126 | NA ± NA |
| Day 8 or 9 | — | NA ± NA | — |
| IU/mL | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Day 2 | 0.1667 ± 0.17308 | 0.8493 ± 0.62139 | 0.9274 ± 0.93426 |
| Day 3 | 0.2579 ± 0.26836 | 1.110 ± 0.52612 | 1.174 ± 0.93910 |
| Day 4 or 5 | 0.3138 ± 0.38416 | 1.180 ± 0.65905 | 1.378 ± 1.1976 |
| Day 6 or 7 | 0.1660 ± 0.28752 | 1.070 ± 0.98879 | NA ± NA |
| percentage of participants | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Day 2 | 57.1 | 100.0 | 77.8 |
| Day 3 | 57.1 | 100.0 | 85.7 |
| Day 4 or 5 | 50.0 | 100.0 | 100.0 |
| Day 6 or 7 | 33.3 | 66.7 | 50.0 |
| Day 8 or 9 | — | 100.0 | — |
| Day 11 or 12 | — | 100.0 | — |
Remission was defined as the time taken to achieve platelet count ≥150,000/μL, which was confirmed by a second normal platelet count ≥150,000/μL and LDH \<2 ULN 48 hours following initial normalization.
| Participants | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Number of Participants Who Achieved Remission Following Normalization of Platelet Count | 9 | 8 | 8 |
Remission was defined as a normal platelet count and LDH \<2 upper limit of normal (ULN) for at least 48 hours following initial normalization of platelet count (acute episode period). Normalization of platelet count was defined ≥150,000/μL, which was confirmed by a second normal platelet count ≥150,000/μL and LDH \<2 ULN.
| percentage of participants | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Percentage of Participants Achieving Remission | 100.0 (69.15 to 100.00) | 100.0 (63.06 to 100.00) | 88.9 (51.75 to 99.72) |
Exacerbation was defined as recurrent thrombocytopenia following a response and requiring a reinitiation of daily plasma exchange treatment after ≥1 day but ≤30 days of no plasma exchange treatment. Data is reported based on Kaplan-Meier estimates. Data was reported for time to first exacerbation in categories for participants enrolled before protocol amendment 4 (from study start up to 11 months) and after protocol amendment 4 (from 11 months up to the EOS).
| days | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| From Study Start up to 11 Months | NA (2.00 to NA) | NA (NA to NA) | 8.0 (5.00 to NA) |
| From 11 Months up to EOS (up to approximately 15 months) | NA (4.00 to NA) | NA (NA to NA) | NA (6.00 to NA) |
Relapse was determined by platelet count or the occurrence after remission of a major clinical event (e.g., Myocardial Infraction (MI), stroke, death) deemed by the investigator to be related to aTTP. Data was reported for time to relapse in categories for participants enrolled before protocol amendment 4 (from study start up to 11 months) and after protocol amendment 4 (from 11 months up to the EOS).
| days | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| From Study Start up to 11 Months | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| From 11 Months up to EOS (up to approximately 15 months) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Exacerbation was determined by platelet count or the occurrence after remission of a major clinical event (e.g., myocardial infarction (MI), stroke, death) deemed by the investigator to be related to aTTP. Data was reported for percentage of participants with exacerbation in categories for participants enrolled before protocol amendment 4 (from study start up to 11 months) and after protocol amendment 4 (from 11 months up to the EOS).
| percentage of participants | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| From Study Start up to 11 Months | 50.0 (6.76 to 93.24) | 0.0 (0.00 to 60.24) | 60.0 (14.66 to 94.73) |
| From 11 Months up to EOS (up to approximately 15 months) | 33.3 (4.33 to 77.72) | 0.0 (0.00 to 60.24) | 33.3 (0.84 to 90.57) |
Relapse was determined by platelet count or the occurrence after remission of a major clinical event (e.g., Myocardial Infraction (MI), stroke, death) deemed by the investigator to be related to aTTP. Data was reported for percentage of participants with exacerbation in categories for participants enrolled before protocol amendment 4 (from study start up to 11 months) and after protocol amendment 4 (from 11 months up to the EOS).
| percentage of participants | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| From Study Start up to 11 Months | 0.0 (0.0 to 60.24) | 0.0 (0.0 to 60.24) | 0.0 (0.0 to 52.18) |
| From 11 Months up to EOS (up to approximately 15 months) | 0.0 (0.0 to 45.93) | 0.0 (0.0 to 60.24) | 0.0 (0.0 to 70.76) |
Major clinical events related to TTP included Death, Stroke, MI and organ dysfunction not normalized within the 90-day observation period which consisted of chronic renal insufficiency, neurologic impairment and neurocognitive deficits.
| percentage of participants | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Renal Insufficiency | 90.0 | 100.0 | 88.9 |
| Neurologic Deficits | 60.0 | 100.0 | 77.8 |
| Brain Injury | 50.0 | 62.5 | 66.7 |
| Death, Stroke and MI | 0 | 0 | 0 |
Major clinical events included clinically relevant bleeding (modified ITP score) or thrombosis at the site of line insertion, adverse reactions to plasma, including citrate reactions, allergic reactions, and transfusion-related acute lung injury (TRALI). Data is reported by summarizing the data for all parameters.
| Participants | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Number of Participants With Major Clinical Events Related to PEX | 6 | 1 | 1 |
| Participants | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Baseline | 7 | 8 | 8 |
| EOS at Month 15 | 3 | 2 | 5 |
| Participants | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Baseline | 6 (0.6 to 3.4) | 4 (1.0 to 1.8) | 7 (0.6 to 4.0) |
| EOS at Month 15 | 3 (0.6 to 0.6) | 3 (0.7 to 1.7) | 2 (4.0 to 4.0) |
Percentages are based on the total number of participants per treatment group that have at least one ADA sample analyzed.
| percentage of participants | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| ADA Positive: up to 3 Months | 80.0 | 62.5 | 88.9 |
| ADA Positive: up to 6 Months | 20.0 | 75.0 | 33.3 |
| Nab Positive: up to 3 Months | 40.0 | 37.5 | 33.3 |
| Nab Positive: up to 6 Months | 30.0 | 37.5 | 22.2 |
AE=any untoward medical occurrence in a participants administered IP that does not necessarily have a causal relationship with the treatment. TEAE=an adverse event with an onset that occurs after receiving study drug. SAE=an AE with any untoward clinical manifestation of signs, symptoms or outcomes which results in death, requires inpatient hospitalization or prolongation of hospitalization, results in persistent or significant disability/incapacity, results in a congenital abnormality/birth defect, important medical event, bronchospasm associated with anaphylaxis, reviewed and confirmed seroconversion for human immunodeficiency virus (HIV), hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis E virus (HEV), or parvovirus B19 (B19V). A product related AE is any event emerging or manifesting at or after the initiation of treatment with an investigational product or medicinal product or any existing event that worsens.
| Participants | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Any TEAEs | 10 | 9 | 8 |
| Specifically Product-Related TEAEs | 0 | 1 | 0 |
| Serious TEAEs | 4 | 1 | 3 |
Vital signs were assessed based on blood pressure, pulse rate, respiratory rate and body temperature.
| Participants | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Number of Participants With Clinically Relevant Changes in Vital Signs | 0 | 0 | 0 |
Clinical chemistry assessed alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin, alkaline phosphatase, blood urea nitrogen, creatinine, and glucose.
| Participants | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Number of Participants With Clinically Relevant Changes in Clinical Chemistry | 0 | 0 | 0 |
Hematology consisted of complete blood count and leukocytes with differential (basophils, eosinophils, lymphocytes, monocytes, neutrophils), mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC) and platelet count.
| Participants | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Number of Participants With Clinically Relevant Changes in Hematology | 0 | 0 | 0 |
Rescue therapy was defined as any product with a known interruption to the pharmacokinetic/ pharmacodynamic (PK/PD) relationship between ADAMTS-13 activity, von Willebrand factor (VWF) activity, and platelet count. If rescue therapy was initiated, the administration of IP (SHP655 or placebo) was suspended for the duration of the study. Number of participants experiencing occurrence of receiving rescue therapy was assessed.
| percentage of participants | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Percentage of Participants Receiving Rescue Therapy | 20.0 | 0 | 22.2 |
Rescue therapy was defined as any product with a known interruption to the PK/PD relationship between ADAMTS-13 activity, VWF activity, and platelet count. If rescue therapy was initiated, the administration of IP (SHP655 or placebo) was suspended for the duration of the study. Number of participants experiencing occurrence in meeting rescue therapy criteria was assessed. Percentage of participants with rescue therapy initiated are based on laboratory criteria and adverse events.
| percentage of participants | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 |
|---|---|---|---|
| Percentage of Participants Meeting Rescue Criteria | 10.0 | 0.0 | 11.1 |
Collected over From start of study drug administration up to end of the study (up to approximately 15 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Post PEX + Placebo 12H Post PEX | 0/10 (0%) | 4/10 (40%) | 10/10 (100%) |
| SHP655 40 IU/kg Post PEX + Placebo 12H Post PEX | 0/9 (0%) | 1/9 (11.1%) | 9/9 (100%) |
| SHP655 40 IU/kg Post PEX + SHP655 40 IU/kg 12H Post PEX | 0/9 (0%) | 3/9 (33.3%) | 6/9 (66.7%) |
| Event | Placebo Post PEX + Placebo 12H Post PEX | SHP655 40 IU/kg Post PEX + Placebo 12H Post PEX | SHP655 40 IU/kg Post PEX + SHP655 40 IU/kg 12H Post PEX |
|---|---|---|---|
| Thrombotic thrombocytopenic purpuraBlood and lymphatic system disorders | 3/10 | 0/9 | 2/9 |
| CholecystitisHepatobiliary disorders | 0/10 | 1/9 | 0/9 |
| PneumoniaInfections and infestations | 0/10 | 1/9 | 0/9 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/10 | 0/9 | 1/9 |
| CholelithiasisHepatobiliary disorders | 1/10 | 0/9 | 0/9 |
| Drug hypersensitivityImmune system disorders | 1/10 | 0/9 | 0/9 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/10 | 0/9 | 0/9 |
| Event | Placebo Post PEX + Placebo 12H Post PEX | SHP655 40 IU/kg Post PEX + Placebo 12H Post PEX | SHP655 40 IU/kg Post PEX + SHP655 40 IU/kg 12H Post PEX |
|---|---|---|---|
| ConstipationGastrointestinal disorders | 1/10 | 3/9 | 1/9 |
| Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders | 3/10 | 0/9 | 0/9 |
| NauseaGastrointestinal disorders | 3/10 | 0/9 | 0/9 |
| PruritusSkin and subcutaneous tissue disorders | 3/10 | 1/9 | 0/9 |
| PyrexiaGeneral disorders | 3/10 | 1/9 | 1/9 |
| Alanine aminotransferase increasedInvestigations | 1/10 | 2/9 | 1/9 |
| DiarrhoeaGastrointestinal disorders | 1/10 | 2/9 | 0/9 |
| Heart rate increasedInvestigations | 0/10 | 2/9 | 0/9 |
| HypokalaemiaMetabolism and nutrition disorders | 0/10 | 2/9 | 0/9 |
| ParaesthesiaNervous system disorders | 0/10 | 2/9 | 0/9 |
Safety Analysis Set (SAS) included all participants randomized, who received any dose of investigational product.
| Age, Continuous(years) | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 | Total |
|---|---|---|---|---|
| Mean | 41.2 ± 10.80 | 51.9 ± 14.81 | 48.4 ± 14.93 | 47.0 ± 13.82 |
| Sex: Female, Male(Participants) | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 | Total |
|---|---|---|---|---|
| Female | 8 | 6 | 5 | 19 |
| Male | 2 | 3 | 4 | 9 |
| Ethnicity (NIH/OMB)(Participants) | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 0 | 1 |
| Not Hispanic or Latino | 10 | 8 | 9 | 27 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Standard of Care (SoC) + Placebo | SoC + SHP655 + Placebo | SoC + SHP655 | Total |
|---|---|---|---|---|
| Race — American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Race — Asian | 0 | 1 | 0 | 1 |
| Race — Black or African American | 4 | 1 | 2 | 7 |
| Race — White | 6 | 5 | 6 | 17 |
| Race — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Race — Other | 0 | 2 | 0 | 2 |
| Race — Missing | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Oct 2019 to primary completion in Aug 2021, 21 months.
Results were first posted in Dec 2022, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Apadamtase alfa
Purpura, Thrombotic Thrombocytopenic →